PODD INSULET CORP

Price Chart

Executive Summary

The Federal Circuit reversed the district court's judgment and permanent injunction against EOFlow, holding that Insulet's trade secret misappropriation claim under the Defend Trade Secrets Act was time-barred because Insulet knew or should have known of the misappropriation before August 3, 2020 (three years before filing suit). The court found undisputed evidence that Insulet had knowledge of EOFlow's access to its trade secrets through a former employee and of striking similarities between the Omnipod and EOPatch 2 by early 2019, triggering the three-year statute of limitations. This ruling vacates the $59.4 million in damages (after reduction) and the permanent injunction that barred EOFlow from commercializing products using Insulet's trade secrets, removing a major overhang on EOFlow's ability to compete in the insulin patch pump market.

Court Ruling Details

Actionable Insight

Key Facts

• Federal Circuit reversed district court's judgment and permanent injunction against EOFlow in Insulet's trade secret misappropriation case
• Court held Insulet's DTSA claim was time-barred because Insulet knew or should have known of misappropriation before August 3, 2020
• Jury had awarded $170M compensatory and $282M exemplary damages, later reduced to $25.8M compensatory and $33.6M exemplary to avoid double recovery with injunction
• Permanent injunction had barred EOFlow from commercializing products using Insulet's trade secrets worldwide
• Court applied access-plus-similarity framework: knowledge that former employee with trade secret access worked for competitor on similar product starts limitations clock
• Insulet had internal emails from March 2019 noting former employees worked on EOPatch 2, and employees described EOPatch 2 as 'cloned our product' after June 2018 ADA conference
• Dissenting opinion argued majority improperly substituted its fact-finding for the jury's and conflated discovery rule with inquiry-notice standard

Financial Impact

Vacated $59.4M in damages (after reduction) and permanent injunction; Insulet loses trade secret protection and competitive moat against EOFlow's EOPatch 2

Risk Factors

• Insulet may seek Supreme Court review, though certiorari is unlikely on a statute-of-limitations ruling
• EOFlow's EOPatch 2 could gain market share in Europe and South Korea, pressuring Omnipod sales
• Loss of trade secret protection may encourage other competitors to enter the patch pump market
• Insulet's patent claims were dismissed without prejudice but are likely time-barred, leaving no remaining IP claims against EOFlow

Market Snapshot

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

US Market Status